Juniper MDD Study

Help test a new depression option

Join the Juniper Major Depressive Disorder (MDD) Study to help researchers test a new option for depression.

Am I eligible? help_outline

Enrolling now!
  • person
    Current primary diagnosis of Major Depressive Disorder (MDD)
  • date_range
    Up to 11 weeks
  • card_giftcard
    Compensation available

Who's eligible

Ages 18-65

U.S. Resident

Own an Android or iPhone smartphone

1-3 inadequate responses to antidepressant treatment in current major depressive episode

Not have a current depressive episode longer than 2 years

What's involved

You'll also receive a physical exam and lab tests at no cost to you.

Receive study drug and/or placebo

Receive investigational drug alone or with SSRI, SSRI alone, or placebo

Speak with your researchers

Four calls to update the research team (Day 1, week 3, 5, & 7)

Check in with a Study Doctor

Four meetings with your study doctor (Week 1, 2, 4, & 6)

What you'll receive:

Compensation available

Will receive study-related care and study drug at no cost

Support from study doctors

Working together to help people impacted by depression.

Verily Life Sciences

Facts about Depression

Shape the future of depression research

Juniper MDD Study

Study FAQs

The Juniper MDD Study is intended to evaluate the effectiveness of a new potential depression option.

Otsuka is the sponsor.

The study is up to 11 weeks, including:

  • Up to a 28-day screening period
  • 6-week study drug period
  • 7-day safety follow up period

Project Baseline is a broad effort to better understand health and prevent disease. This study is a part of the broader initiative to better understand new possible treatments for depression.

If qualified, you will take the investigational drug or placebo. You will also have four phone calls to update the research team (day 1, week 3, 5, & 7), along with four office visits with your study doctor to discuss your experience (week 1, 2, 4, & 6). You’ll also receive a physical exam and lab tests at no cost to you.

You will receive the investigational drug or placebo.

No, it will not cost you anything to participate.

You are not eligible if you:

  • Are breast-feeding and/or have a positive pregnancy test result before receiving the investigational drug.
  • Are participating in therapy within 3 months leading up to screening for the study.
  • Have been diagnosed with a disorder that is likely to:
    • require treatment that conflicts with this study.
    • or impact efficacy or safety assessments (including, but not limited to, experiencing hallucinations, delusions, or any psychotic symptomatology, bipolar disorder, schizophrenia, or other psychotic disorder).

Your identity and medical information will be kept confidential. We take your privacy and confidentiality seriously. A Google account is required to join this study and while Google provides the computing, analytics, and data handling power, Google will not sell your information. All your information will be stored in a secure, encrypted database with restricted access. We will not share any information with your insurance or medical providers without your consent. Please see our Privacy Policy for full details.

No. We will not share any information with your insurance or doctor without your consent.

The protocol number is 405-201-00062.